Pasireotide

Pasireotide is a synthetic cyclohexapeptide somatostatin analog developed by Novartis that has a unique receptor binding profile compared to first-generation somatostatin analogs (octreotide and lanreotide). While octreotide and lanreotide bind primarily to SSTR2, pasireotide has high binding affinity for four of the five somatostatin receptor subtypes (SSTR1, 2, 3, and 5), with particularly strong affinity for SSTR5 — approximately 40 times higher than octreotide. This broader receptor binding profile gives pasireotide therapeutic activity in conditions that do not respond well to first-generation analogs.

The high SSTR5 affinity is particularly relevant for Cushing's disease, where corticotroph adenomas predominantly express SSTR5 rather than SSTR2. Pasireotide was the first pituitary-directed medical therapy approved by the FDA for the treatment of Cushing's disease (2012), in patients for whom pituitary surgery is not an option or has not been curative. By acting on SSTR5 receptors on corticotroph adenoma cells, pasireotide suppresses ACTH secretion and consequently reduces cortisol levels.

In acromegaly, a long-acting release (LAR) formulation of pasireotide was approved for patients who have had an inadequate response to first-line somatostatin analogs. The PAOLA study demonstrated that pasireotide LAR provided superior biochemical control (normalization of GH and IGF-1) compared to continued octreotide LAR or lanreotide Autogel in patients inadequately controlled on first-generation analogs.

The most significant limitation of pasireotide is its effect on glucose metabolism. Due to its SSTR5-mediated suppression of insulin secretion combined with reduced incretin effect, pasireotide causes hyperglycemia in approximately 70% of treated patients, with many requiring initiation or intensification of antidiabetic therapy.